Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or in Combination With Albumin-bound Paclitaxel in Patients With Recurrent or Metastatic Triple Negative Breast Cancer

NCT07281976 is registered in ClinicalTrials.gov with Nanjing Leads Biolabs Co.,Ltd as lead sponsor.

NCT NCT07281976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07281976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or in Combination With Albumin-bound Paclitaxel in Patients With Recurrent or Metastatic Triple Negative Breast Cancer
Lead sponsor
Nanjing Leads Biolabs Co.,Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 27, 2026
Completion date
December 31, 2027
Enrollment
220 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer